Miranda Jayne Toledano - 29 Dec 2025 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role: Chief Executive Officer, Director
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Issuer symbol: ENTX
Transactions as of: 29 Dec 2025
Net transactions value: +$19,912
Form type: 4
Filing time: 30 Dec 2025, 06:01:25 UTC
Previous filing: 07 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Toledano Miranda Jayne	Chief Executive Officer, Director	KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM, ISRAEL	/s/ Dana Yaacov-Garbeli, Attorney-in-Fact	30 Dec 2025	0001686530

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Purchase	$19,912	+11,000	+2.6%	$1.81	426,575	29 Dec 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.75 to $1.82, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.75 to $1.82, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.